{"schema":"sb.node.v1","id":"sb:e/7404839fb1f69117a214787b","kind":"entity","label":{"text":"t-dxd","locale":"en"},"identity":{"anchor":"label:en:t-dxd","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T17:30:17.444527+00:00","snapshot":"deploy 8b85b32669420cec000e55a4e0a71234807a9541"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":16,"separatePublishers":3,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.188,"named":3,"of":16,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only","blind":["only 19% of the 16 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-05-16","to":"2026-10-06","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.188: about 81% of mentions carry no typed assertion"]}},"dimensions":{"domains":["society_news","pharma-regulatory"],"activeDays":14,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":3,"byKind":{"observation":3},"items":[{"id":"sb:o/fd54375928c464aee95c5da4","kind":"observation","label":"The ASCO Post · 2026-09-22 · Metastatic HER2-Mutant NSCLC First-Line T-DXd","url":"https://ascopost.com/videos/iaslc-wclc-2026/metastatic-her2-mutant-nsclc-first-line-t-dxd/"},{"id":"sb:o/884db660dae4a990db9cd541","kind":"observation","label":"The ASCO Post · 2026-09-10 · Additional Safety Analysis of DESTINY-Breast05: What Did It Show?","url":"https://ascopost.com/issues/september-10-2026/additional-safety-analysis-of-destiny-breast05-what-did-it-show/"},{"id":"sb:o/870e5dda96c351a5ed1ca128","kind":"observation","label":"FDA Drug News · 2026-05-16 · [APPROVAL] FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer","url":"http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-two-separate-indications-fam-trastuzumab-deruxtecan-nxki-her2-positive-early-stage"}],"cursor":null,"order":"newest first; we keep the 3 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with her2 (16 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c61013bb45318056f425bf25"},{"kind":"relation","label":"co-mentioned with her2-directed (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9e2ace378503933428c4b281"},{"kind":"relation","label":"co-mentioned with egfr (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/cccfd1bbfbacd506a9697d39"},{"kind":"relation","label":"co-mentioned with lung cancer (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/43a1673bf24cce6fdb8c6e2c"},{"kind":"relation","label":"co-mentioned with egfr-mutated (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/dc4295128e8b95d077a0d7e5"},{"kind":"relation","label":"co-mentioned with her2-mutant (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/52ea5b971d3817fd284248d5"},{"kind":"relation","label":"co-mentioned with cancer center (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7e54f05ca9c6e155aad6776b"},{"kind":"relation","label":"co-mentioned with dana-farber cancer institute (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8504fa0db7f77ab3630e520a"},{"kind":"relation","label":"co-mentioned with ros1-positive (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a67518b0cfdc45d40f4e0e4e"},{"kind":"relation","label":"co-mentioned with wclc (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/00f9ae4d5e52657972fb4929"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/7404839fb1f69117a214787b","mcp":"traverse {\"id\":\"sb:e/7404839fb1f69117a214787b\"}","page":"/entity/t-dxd/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7404839fb1f69117a214787b\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7404839fb1f69117a214787b\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7404839fb1f69117a214787b\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7404839fb1f69117a214787b\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}